Amino Acid Composition for Coagulation Dysfunction in MODS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coagulation disorder-induced hemorrhage, particularly in multiple organ dysfunction syndrome (MODS), are ineffective, leading to high mortality rates due to coagulation dysfunction and inability of traditional coagulation drugs to directly address the issue, especially in severe trauma and infection cases.
Innovation Solution
A pharmaceutical composition containing L-ornithine, aspartic acid, arginine, and high doses of vitamin B6, along with other amino acids and vitamins, is administered to support the intrinsic coagulation pathway, neutralize harmful free radicals, and restore metabolic balance, thereby promoting the recovery of coagulation factors and liver function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional coagulation drugs are used to treat hemorrhage in MODS patients, then coagulation function should be improved, but the drugs cannot directly address the underlying metabolic dysfunction and liver failure causing the coagulation disorder
Solution Approach 1:
The patent administers amino acids and vitamins before coagulation factors are depleted, aiming to prevent the metabolic dysfunction that leads to coagulation failure. By providing building blocks for liver function and coagulation factor synthesis in advance, the treatment addresses the root cause before hemorrhage becomes severe.
Solution Approach 2:
The patent uses amino acids and vitamins as intermediaries to bridge the gap between metabolic dysfunction and coagulation failure. These substances mediate the restoration of liver function and coagulation factor synthesis, rather than directly replacing coagulation factors themselves.
2Reliability
If expensive organ support devices are used for extracorporeal circulation, then patient survival may be supported, but the treatment cost increases significantly
Solution Approach 1:
The patent uses inexpensive, readily available amino acids and vitamins that can be administered intravenously, replacing the need for expensive extracorporeal circulation devices. These nutritional substrates are metabolized and replenished continuously, providing sustained effect without requiring costly mechanical support systems.
Solution Approach 2:
The patent changes the treatment approach from mechanical life support to metabolic support by altering the fundamental parameter of what is being supplemented. Instead of supporting circulation mechanically, the treatment supports metabolism chemically through amino acid and vitamin administration, achieving similar survival outcomes at lower cost.
3Reliability
If high doses of amino acids and vitamins are administered, then metabolic balance and coagulation factor synthesis should be restored, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The patent uses amino acids and vitamins that serve multiple functions: they provide building blocks for coagulation factor synthesis, support liver regeneration, correct metabolic acidosis, and improve overall metabolic balance. This multi-functionality reduces the need for multiple separate treatments and simplifies the overall therapeutic approach despite the multiple components involved.
Data Source
AI summary
The present invention belongs to the emergency treatment field of critically ill patients and involves a pharmaceutical composition used to treat coagulation disorder hemorrhage and its purpose and methods to treat the patients bleeding due to coagulation disorder. Containing L-ornithine 0.5∼8g, aspartic acid 1∼5g, arginine 3~10g and vitamin B6 3-10g per unit, the pharmaceutical composition is effective in treating the hemorrhagic patients caused by coagulation dysfunction, especially in treating critically ill patients.